However, in a rare soft-tissue sarcoma, namely in alveolar soft part sarcoma, PD-L1 expression rate is higher, and anti–programmed death ligand 1 (PD-L1) agent atezolizumab elicited sustained response in one-third of the patients in a phase-2 study [41]. This evidence concerns the gene CD274 and alveolar soft part sarcoma.